PRO is defined as any report of the status of a pt’s health condition that comes directly from the pt. Besides the viroimmunological outcomes, PRO measurements are an important tool for long term control of HIV infection, since they represent benefits over provider-reported outcomes in terms of symptoms, quality of life (QoL) and health. To date, the impact on pts’ health of E/C/F/TDF has been described in clinical trials but real-life data are lacking. We conducted a longitudinal evaluation of PROs in a cohort of HIV+ pts starting E/C/F/TDF.
Patient-Reported Outcomes (PROs) evalutation among HIV-infected (HIV+) patients (pts) starting elvitegravir/cobicistat/emtricitabina/tenofovir disoproxil fumarate (E/C/F/TDF).
G. Nunnari;G. F. Pellicanò.
2018-01-01
Abstract
PRO is defined as any report of the status of a pt’s health condition that comes directly from the pt. Besides the viroimmunological outcomes, PRO measurements are an important tool for long term control of HIV infection, since they represent benefits over provider-reported outcomes in terms of symptoms, quality of life (QoL) and health. To date, the impact on pts’ health of E/C/F/TDF has been described in clinical trials but real-life data are lacking. We conducted a longitudinal evaluation of PROs in a cohort of HIV+ pts starting E/C/F/TDF.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
